ERBB2 and breast cancer: Neratinib is an irreversible small molecule inhibitor of HER1, HER2 and HER4 tyrosine kinases, approved for the extended adjuvant treatment of women with early-stage and metastatic HER2 + breast cancer (Oh and Bang, 2020).